Abbott (NYSE: ABT) today announced it has received CE Mark in Europe for the Volt™ PFA System to treat patients battling atrial fibrillation (AFib). With the earlier-than-expected CE Mark, Abbott has ...
Medical Device Network on MSN4d
Abbott accelerates PFA market competition in Europe with early Volt approvalThough late to the party compared to other industry leaders, Abbott joins a pulsed field ablation market poised for ...
The Volt PFA system. [Image courtesy of Abbott] Abbott (NYSE: ABT) + announced it received CE mark approval in Europe for its ...
The company is first rolling out the use of the Volt system among European Union doctors who have already gained experience ...
Abbott Laboratories (NYSE: ABT) stock was in fine health on the second-to-last trading day of the week, thanks to news from ...
With PFA becoming physicians’ preferred ablation method for treating AFib, Abbott is pushing to catch up with rival systems ...
Abbott announced it has received CE Mark in Europe for the Volt PFA System to treat patients battling atrial fibrillation (AFib). With the earlier-than-expected CE Mark, Abbott has begun commercial ...
Abbott is joining the worldwide race to make pulsed field ablation the standard procedure for atrial fibrillation with an ...
Abbott (ABT) announced it has received CE Mark in Europe for the Volt PFA System to treat patients battling atrial fibrillation. With the ...
Abbott's Volt™ PFA System is designed to provide a new therapy option for people battling heart rhythm disorders such as atrial fibrillation Pulsed field ablation – or PFA – uses high energy ...
(RTTNews) - Abbott (ABT) Thursday announced it has received CE Mark in Europe for the Volt PFA System to treat patients battling atrial fibrillation (AFib). With the earlier-than-expected CE Mark ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback